Lampert Mark N
SEC-identified person · CIK 1233840 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Kymera Therapeutics, Inc. KYMR | Director | filed 2020–2026 |
| Olema Pharmaceuticals, Inc. OLMA | Director | filed 2020–2026 |
| Moonlake Immunotherapeutics MLTX | Director | filed 2022–2026 |
| Xoma Royalty Corp XOMAD | Director | filed 2017–2026 |
| Vital Therapies INC VTL | Director | filed 2026–2026 |
| Repare Therapeutics Inc. RPTX | Officer | filed 2021–2026 |
| Essa Pharma Inc. EPIX | Officer | filed 2022–2025 |
| Glycomimetics INC GLYC | Officer | filed 2017–2025 |
| Allakos Inc. ALLK | Officer | filed 2024–2025 |
| Pieris Pharmaceuticals, INC. PVLA | Officer | filed 2018–2024 |
| 4D Molecular Therapeutics, Inc. FMDT | Officer | filed 2022–2024 |
| Tokai Pharmaceuticals Inc TKAI | Officer | filed 2020–2024 |
| Third Harmonic Bio, Inc. THRD | Officer | filed 2022–2024 |
| Rain Therapeutics Inc. RAIN | Director | filed 2021–2024 |
| Therapeutics Acquisition Corp. TXAC | Officer | filed 2023–2023 |
| Engene Therapeutics Inc. ENGN | Officer | filed 2023–2023 |
| CTI Biopharma Corp ctic | Director | filed 2015–2023 |
| Structure Therapeutics Inc. GPCR | Officer | filed 2023–2023 |
| Cullinan Therapeutics, Inc. CGEM | Officer | filed 2022–2023 |
| Verastem, Inc. VSTM | Officer | filed 2022–2022 |
| Merus N.V. MRUS | Officer | filed 2020–2021 |
| Five Prime Therapeutics, INC. FPRX | Officer | filed 2019–2021 |
| Infinity Pharmaceuticals, INC. INFI | Director | filed 2016–2021 |
| Cytomx Therapeutics, Inc. CTMX | Officer | filed 2020–2021 |
| Ideaya Biosciences, Inc. IDYA | Officer | filed 2020–2021 |
| Cytokinetics INC CYTK | Officer | filed 2019–2020 |
| Principia Biopharma Inc. PRNB | Officer | filed 2020–2020 |
| Calithera Biosciences, Inc. CALA | Officer | filed 2019–2020 |
| Concert Pharmaceuticals, INC. N/A | Officer | filed 2017–2019 |
| Immune Design Corp. IMDZ | Officer | filed 2018–2018 |
| Syndax Pharmaceuticals Inc SNDX | Officer | filed 2017–2018 |
| Arqule INC arql | Officer | filed 2009–2018 |
| Xenon Pharmaceuticals Inc. XENE | Officer | filed 2016–2018 |
| Regulus Therapeutics Inc. RGLS | Officer | filed 2017–2017 |
| Orthologic Corp OLGC | Officer | filed 2011–2017 |
| Nivalis Therapeutics, Inc. NVLS | Officer | filed 2017–2017 |
| Oncothyreon Inc. ONTY | Director | filed 2013–2016 |
| Chemocentryx, Inc. CCXI | Officer | filed 2012–2015 |
| Targacept INC TRGT | Officer | filed 2009–2015 |
| Array Biopharma INC ARRY | Officer | filed 2011–2014 |
| Ligand Pharmaceuticals INC LGNDD | Officer | filed 2009–2014 |
| Tobira Therapeutics, Inc. TBRA | Officer | filed 2014–2014 |
| Palatin Technologies INC PTN | Officer | filed 2011–2014 |
| Rigel Pharmaceuticals INC RIGL | Officer | filed 2013–2013 |
| Neurocrine Biosciences INC NBIX | Officer | filed 2010–2012 |
| Kent International Holdings INC KNTH | Officer | filed 2011–2011 |
| Icagen INC ICGN | Officer | filed 2011–2011 |
| Celera Corp CRA | Officer | filed 2011–2011 |
| Supergen INC SUPG | Officer | filed 2010–2010 |
| Facet Biotech Corp FACT | Officer | filed 2009–2010 |
| Zalicus Inc. ZLCS | Officer | filed 2009–2009 |
| Medicinova INC MNOV | Officer | filed 2009–2009 |
| Avigen INC \DE avgn | Officer | filed 2009–2009 |
| Neurobiological Technologies INC /CA/ NTII | Officer | filed 2009–2009 |
| Adolor Corp adlr | Officer | filed 2009–2009 |
| Dynavax Technologies Corp dvax | Officer | filed 2009–2009 |
| Repligen Corp RPGN | Officer | filed 2009–2009 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.